MX381497B - Composiciones vacuna. - Google Patents

Composiciones vacuna.

Info

Publication number
MX381497B
MX381497B MX2015000442A MX2015000442A MX381497B MX 381497 B MX381497 B MX 381497B MX 2015000442 A MX2015000442 A MX 2015000442A MX 2015000442 A MX2015000442 A MX 2015000442A MX 381497 B MX381497 B MX 381497B
Authority
MX
Mexico
Prior art keywords
vaccine compositions
protecting
useful
relates
human subject
Prior art date
Application number
MX2015000442A
Other languages
English (en)
Spanish (es)
Other versions
MX2015000442A (es
Inventor
Alain Bouckenooghe
Jean Lang
Mélanie Saville
Nadia Tornieporth
Remi Forrat
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2015000442A publication Critical patent/MX2015000442A/es
Publication of MX381497B publication Critical patent/MX381497B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015000442A 2012-07-24 2013-07-24 Composiciones vacuna. MX381497B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305907 2012-07-24
EP12305912 2012-07-25
PCT/EP2013/065667 WO2014016360A1 (en) 2012-07-24 2013-07-24 Vaccine compositions

Publications (2)

Publication Number Publication Date
MX2015000442A MX2015000442A (es) 2015-03-12
MX381497B true MX381497B (es) 2025-03-12

Family

ID=48875047

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000442A MX381497B (es) 2012-07-24 2013-07-24 Composiciones vacuna.
MX2021004211A MX2021004211A (es) 2012-07-24 2015-01-09 Composiciones vacuna.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021004211A MX2021004211A (es) 2012-07-24 2015-01-09 Composiciones vacuna.

Country Status (11)

Country Link
US (2) US20150196631A1 (https=)
EP (2) EP2877208B1 (https=)
JP (2) JP2015524421A (https=)
KR (2) KR20150036592A (https=)
CN (1) CN104812407B (https=)
AU (1) AU2013295014B2 (https=)
MX (2) MX381497B (https=)
MY (2) MY168959A (https=)
PH (1) PH12014502840B1 (https=)
SG (2) SG10201912291YA (https=)
WO (1) WO2014016360A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150036593A (ko) * 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CN107405392B (zh) * 2015-02-09 2021-05-18 中央研究院 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
EP3147294B1 (en) * 2015-09-24 2020-04-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
EP3382012A4 (en) * 2015-11-27 2019-07-03 KM Biologics Co., Ltd. LIVING VIRUS WITH A BANK OF ATTENUATED TREES OF DENGUEVIRUS AND DENGUE VACCINE THEREFORE AS ANTIGENE
US11007261B2 (en) * 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN116334070B (zh) * 2023-02-15 2026-02-06 天津大学 融合蛋白的应用和细胞融合的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422A (en) 1848-02-01 Spark-arrester
US109A (en) 1836-12-15 Erawijtg
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
HU228705B1 (en) 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱3型ウイルスワクチン
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
WO2002102828A2 (en) 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
KR101194818B1 (ko) * 2002-01-15 2012-10-25 사노피 파스테르 바이오로직스, 엘엘씨 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20080193477A1 (en) 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
CN101360821A (zh) * 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition

Also Published As

Publication number Publication date
PH12014502840A1 (en) 2015-02-23
EP3932422A1 (en) 2022-01-05
KR20200067938A (ko) 2020-06-12
AU2013295014B2 (en) 2018-01-18
CA2878682A1 (en) 2014-01-30
EP2877208B1 (en) 2021-05-12
JP2015524421A (ja) 2015-08-24
KR20150036592A (ko) 2015-04-07
AU2013295014A1 (en) 2015-01-29
SG11201500412TA (en) 2015-02-27
EP2877208A1 (en) 2015-06-03
CN104812407A (zh) 2015-07-29
MX2021004211A (es) 2021-05-27
PH12014502840B1 (en) 2015-02-23
MY197723A (en) 2023-07-10
CN104812407B (zh) 2022-11-22
MX2015000442A (es) 2015-03-12
WO2014016360A1 (en) 2014-01-30
US20150196631A1 (en) 2015-07-16
HK1212906A1 (zh) 2016-06-24
JP2019151636A (ja) 2019-09-12
JP6830118B2 (ja) 2021-02-17
US20190201517A1 (en) 2019-07-04
MY168959A (en) 2019-01-28
SG10201912291YA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
MX381497B (es) Composiciones vacuna.
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
EP2890312A4 (en) IMPLANT FOR CALCANUS EOSTEOTOMY
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015002651A2 (pt) composições cosméticas
DK2912074T3 (da) Dermal injicerbar steril sammensætning
PT2928489T (pt) Composição imunogénica
BR112014028282A2 (pt) composição cosmética anidra e método cosmético
BR112015012907A2 (pt) composição de cuidado pessoal
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
EP2895139A4 (en) COMPOSITIONS AND METHODS FOR DENTAL TREATMENT
EP2876161A4 (en) VACCINE
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
EP2825196A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
EP2897613A4 (en) TREATMENT COMPOSITIONS
EP2931304A4 (en) WT1 VACCINE
ME03029B (me) Kompozicije koje obuhvataju vortioksetin i donepezil
UY34702A (es) Composiciones y métodos agrícolas u hortícolas
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
DK3175852T3 (da) Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
FR2992161B1 (fr) Protection intra-buccale
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS
EP2851085A4 (en) STERILIZED COMPOSITION